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Abstract

Background

Background: The COVID-19 pandemic remains an ongoing threat to global public health. Q-Griffithsin (Q-GRFT) is
a lectin that has demonstrated potent broad-spectrum inhibitory activity in preclinical studies in models of Nipah
virus and the beta coronaviruses SARS-CoV, MERS-CoV, and
SARS-CoV-2.

Over the past 2 decades, three coronaviruses of the Betacoronavirus genus have emerged as serious human pathogens.
The ongoing COVID-19 pandemic has caused over 620 million infections globally and over 1,060,000 deaths to date in
the United States.

Methods: Here, we propose a clinical trial design to test
the safety, pharmacokinetics (PK), and tolerability of intranasally administered Q-GRFT for the prevention of SARSCoV-2 infection as a prophylaxis strategy. The initial Phase
1a study will assess the safety and PK of a single dose of
intranasally administered Q-GRFT. If found safe, the safety,
PK, and tolerability of multiple doses of intranasal Q-GRFT
will be assessed in a Phase 1b study. Group 1 participants
will receive 3 mg of intranasal Q-GRFT (200 µL/nostril) once
daily for 7 days. If this dose is tolerated, participants will be
enrolled in Group 2 to receive 3 mg twice daily for 7 days.
Secondary endpoints of the study will be user perceptions,
acceptability, and the impact of product use on participants’
olfactory sensation and quality of life.

The virus that causes COVID-19, SARS-CoV-2, replicates
efficiently in the upper respiratory tract—the nasopharynx
and oropharynx—as well as in the lungs and gastrointestinal
tissue.[1] High viral replication in the nasopharynx in the
early stages of infection, prior to symptom onset, accounts
for the high transmissibility of SARS-CoV-2. While ocular
transmission has been reported [2–5], respiratory aerosol
particles are the most frequent sources of human transmission events.[6, 7] Consequently, the development of an intranasal spray that inhibits replication of virus in the upper
respiratory tract is likely an effective strategy to curb virus
spread. In addition, this strategy will be complementary to
vaccine approaches and biomedical interventions, such as
personal protective equipment (PPE) and measures such as
social distancing and frequent hand washing, in eliminating
the pandemic.

Discussion: Results from this study will support further development of Q-GRFT as a prophylactic against respiratory
viral infections in future clinical trials.

The PREVENT-CoV (PRe-Exposure prevention of Viral ENTry of CoronaViruses) study seeks to demonstrate feasibility
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for application of an intranasal drug administration approach
as a technology to prevent the establishment of upper respiratory infection. This study will be the first-in-human application of Q-GRFT as an intranasal product.
Q-GRFT is an oxidation-resistant variant of Griffithsin
(GRFT), a lectin initially extracted from red marine algae:
Grifithsia sp.[8] GRFT and the engineered oxidation-resistant
variant Q-GRFT, are manufactured using recombinant methods in Nicotiana benthamiana plants.[8] GRFT remains remarkably stable in the environment due to its thermal melting temperature of over 78 °C. The lectin resists digestion by
human and bacterial proteases.[9, 10] Furthermore, GRFT has
demonstrated negligible in vitro and in vivo host toxicity.[11]
With broad-spectrum antiviral activity, GRFT and Q-GRFT
are thought to bind oligomannose glycans that represent a
significant fraction of the N -linked glycan molecules present
on the heavily glycosylated coronavirus S protein.[12] GRFT
strongly inhibits viral entry by binding to a broad array of
coronaviruses, including SARS-CoV [13], MERS-CoV [14, 15],
and SARS-CoV-2.[16, 17] GRFT also targets high-mannose
glycan structures present on many pathogenic enveloped
viruses—including nipah virus [18], hantavirus [19], influenza virus [20], human immunodeficiency viruses (HIV)
types 1 and 2, herpes simplex virus type 2 (HSV-2), hepatitis
C virus (HCV), Japanese encephalitis virus (JEV), and porcine
epidemic diarrhea virus (PEDV)—while exhibiting a remarkable safety profile.[9, 21–28]
Our overarching goal is to develop Q-GRFT, the active
pharmaceutical ingredient (API), as a non-vaccine, broadspectrum pre- and post-exposure prophylactic against respiratory virus infections (including SARS-CoV-2) in the form of
a daily administered nasal spray product. While highly effective vaccines against SARS-CoV-2 are available, the pandemic
persists due to both breakthrough infections and vaccine
hesitancy.[29–31] Additional tools for prevention are needed
both to address risk of SARS-CoV-2 infection in highly vulnerable populations, such as organ transplant recipients, and
to prepare for the next respiratory viral pandemic. To this
end, an intranasal spray product such as Q-GRFT would provide a much-needed strategy for infection prevention, especially in light of the constant evolution of SARS-CoV-2, which
will inevitably prolong the pandemic. While other studies have proposed developing intranasal products for utility
against SARS-CoV-2 [32–35], our program is the first to evaluate intranasal administration of the Q-GRFT lectin and will
establish nasal pharmacokinetic (PK) characteristics for this
drug candidate when administered via this route.
The rationale for the development of a Q-GRFT intranasal
spray is based upon several criteria. Prophylactic intranasal
spray products are designed for the deposition of medications
locally in nasal cavities or systemically. Local drug adminis-

Univ Louisville J Respir Infect | Vol. 6, iss. 1: a22

Intranasal Q-Griffithsin for COVID-19 Prophylaxis

tration, the primary focus of our product, likely prevents or
at least significantly reduces the acquisition of respiratory
infections with a high concentration of product in the respiratory cavity. Local drug delivery is also a logical choice
of product administration for viral respiratory infections, including SARS-CoV-2, whose initial point of entry/infection
in the body occurs predominantly via the nasal cavity. Even
though Q-GRFT may be subjected to local enzymatic activity in the nasal environment, studies elsewhere have demonstrated the lectin’s ability to withstand and avoid degradation
in the presence of protease activity.[36] Additionally, nasal
administration is a convenient, easy-to-use approach and is
widely accepted as a method of drug administration for a variety of disease processes [37, 38], even as chronic therapy.
Against this background, intranasal Q-GRFT delivery is an
additive strategy and approach to the prevention of coronaviruses infection and will be synergistic with other proposed interventions, such as vaccines and PPE.
Here, we outline the clinical protocol for the planned
PREVENT-CoV Phase 1a/1b clinical study, which will evaluate the safety, tolerability, and pharmacokinetics of intranasally administered Q-GRFT in healthy male and female
volunteers. Secondary endpoints for the study will include
user perceptions, acceptability, and the impact of product use
on participants’ olfactory sensation and quality of life. The
data generated from this study will support further development of Q-GRFT in future clinical studies as a nasally administered drug candidate prophylactic against coronavirus
infection.

Methods
Study objectives
The primary objective of this first-in-human intranasal exposure study is to evaluate the safety, tolerability, and PK of
Q-GRFT administered by intranasal spray. Secondary objectives include the assessment of user perceptions and acceptability and the impact of product use on participants’ olfactory sensation and quality of life.
Clinical study design
The Phase 1a study will be a randomized, double-blind,
single-site trial, with participants assigned to receive a single dose of either placebo or Q-GRFT drug product. A safety
evaluation of the single dose exposure will be performed. If
the dose is found to be safe and tolerable, additional participants will be enrolled to receive multiple doses of intranasal
Q-GRFT daily in a Phase 1b study for 7 days.
In the Phase 1a study (Figure 1), 18 participants will be ranNabeta et al. (2022) | 2
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Visit 1
Visit 0

≤4 days

Screening of participants

Enrollment, single-dose exposure, and sample collection;
n=18 randomized to Q-GRFT
intranasal spray or placebo
(2:1)

PK sampling at 1 h and 6 h

1 day
Visit 2
24 h post-dose safety review
and PK sampling

Phase 1a
First human exposure
n=18
Arm 1: 12 active
Arm 2: 6 placebo

2 days
Visit 3
Final safety review and PK
sampling

2–3 weeks

Select dose of Q-GRFT for
Phase 1b multi-dose safety
and PK study

Visit 4
Study exit call to assess any
AEs

Figure 1. Schematic of phase 1a study design. Abbreviations: AE, adverse event; PK, pharmacokinetics.
Table 1. Phase 1a study arms.

Arm

n

Method of assignment

1
2

12
6

Randomized, double-blind
Randomized, double-blind

Study product

Dosing

Q-GRFT intranasal spray (7.5 mg/mL)
Placebo intranasal spray

Single dose, one time
Single administration

domly assigned 2:1 to either Study Arm 1 or 2 to receive either a single dose of study product or placebo under direct observation (Table 1). This is a small study, and the proposed
sample size will allow the detection of any differences following drug administration in both active drug and placebotreated arms. Due to the 2:1 randomization, stratification
was balanced to safeguard for extreme allocation distribution
(such as all females being assigned to the placebo arm). Although a “healthy population” will be enrolled, biological sex
(male, female) and race (white and other) will be considered
as stratification factors. In the placebo arm, the goal is to enroll three males and three females, with the group comprising
four white persons (split between male and female) and two
others (split between male and female); enrollment for the
treatment arm will be double the distribution in the placebo
arm. Participants in Arm 1 will receive a single dose of QGRFT study product, delivered intranasally as two sprays
(200 µL per nostril), for a total dose of 3.0 mg. Participants in
Arm 2 will receive a single dose of placebo product, delivered
intranasally as two sprays per nostril. This intranasal product contains the same ingredients as the study product minus
the active Q-GRFT component. Following administration of
the intranasal product in both arms, PK sampling will be performed at multiple time points (1 hour, 6 hours, 24 hours, and
3 days post dose administration), followed by safety reviews
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after 24 hours, 3 days, and 2–3 weeks later by phone call.∗
Phase 1b will be an open-label dose-escalation study assessing the safety, tolerability, and pharmacokinetics (PK) of a
multiple-dose schedule of Q-GRFT intranasal spray AIP.
Up to 24 healthy participants will be enrolled and assigned
to either of two groups to receive treatment (Figure 2a and
2b). In Group 1, up to 12 participants will receive a dose of 3.0
mg intranasal Q-GRFT, administered once daily as 2 sprays
(100 µL/ spray) in each nostril for 7 days (Table 2). Group 1
participants will undergo PK sampling (nasal and nasopharyngeal fluids) at baseline (enrollment visit); on days 1, 2, 4,
and 7 (pre-dose, 1 hour, 6 hours, and 10 hours after the final dose); day 8, and day 9 following the final dose. Blood
for evaluation of systemic exposure will be collected at baseline, on days 1 and 4, and on day 7 upon dose completion. A
safety review will be performed after dosing in Group 1 prior
to enrolling subjects in Group 2.
In Group 2, up to 12 participants will receive a total of 6.0
mg intranasal Q-GRFT, administered as 3.0 mg twice daily
(3.0 mg BID) with 2 sprays (100 µL/ spray) in each nostril
∗ Trial

status update: following determination that the single clinical dose
administered was safe and acceptable, the study advanced to Phase 1b for
assessment of multiple dosing schedules and strategies for Q-GRFT.
Nabeta et al. (2022) | 3
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≤5 days

Enrollment and first-dose
exposure at clinic and sample
collection
Training will be provided
to participants for selftreatment daily at home

Group 1

Blood draws for safety review,
anti-drug antibodies, and exploratory nasal antibodies

Visit 7
Safety review and 48 h PK
sampling

Visit 6

1 day

Safety review and 24 h PK
sampling*

Visit 5

Group 1:
Minimum 9–12 volunteers
Two sprays each nostril
Once per day
For 7 days
PK sampling at 1 h, 6 h, and
10 h post dose

1 day

1 day

Figure 2. Schematic of phase 1b study design. Abbreviations: PK, pharmacokinetics.

3–4 weeks

Group 1: minimum 9–12 participants
Q-GRFT intranasal treatment: 3.0 mg once daily dosing

Phase1b
Open-label multi-dose safety and PK study
n=18–24
2 groups of minimum 9–12 participants
(No placebo)

Screening of participants

Visit 0

Visit 1

1 day

1 day

1 day

*Optional rectal sampling

7th (final) dose; safety review;
and 1 h, 6 h, and 10 h PK sampling

Visit 4

6th dose at home

5th dose at home

1 day

4th dose, interim safety review, pre-dose and 1 h postdose PK sampling

Visit 3

3rd dose at home

1 day

2nd dose, safety review, and
24 h PK sampling

Visit 2
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≤5 days

Group 2

Blood draws for safety review,
anti-drug antibodies and exploratory nasal antibodies

Visit 8

3–4 weeks

Safety review and 24 h PK
sampling*

Visit 6

Group 2:
Minimum 9–12 volunteers
Two sprays each nostril
Twice per day
For 7 days

Figure 2 (cont’d).

Safety review and 48 h PK
sampling

Visit 7

1 day

Group 2: minimum 9–12 participants
Q-GRFT Intranasal Treatment: 3.0 mg twice daily dosing

Phase1b
Open-label multi-dose safety and PK study
n=18–24
2 groups of minimum 9–12 participants
(No placebo)

Screening of participants

Visit 0

Visit 1
Enrollment and first-dose
exposure at clinic and sample
collection
Training will be provided
to participants for selftreatment daily at home

1 day

1 day

*Optional rectal sampling

Final 13th dose; safety review;
and 1 h, 6 h, 10 h PK sampling

Visit 5

1 day

9th–12th doses at home

2 days

Interim safety review, 7th
dose, pre-dose and 1 h postdose PK sampling, followed
by 8th dose at home

Visit 4

1 day

5th and 6th doses at home

1 day

3rd dose, safety review, and
24 h PK sampling, followed by
4th dose at home

Visit 3

1 day

2nd dose; safety review; and
PK sampling at 1 h, 6 h and 10
h post dose

Visit 2
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Table 2. Phase 1b study arms.

Arm

n

Method of assignment

Study product

Dosing

1

12

Open-label

Q-GRFT intranasal spray (7.5 mg/ mL)

Open-label

Q-GRFT intranasal spray (7.5 mg/ mL)

Multiple doses, two sprays per nostril
(200 µL per nostril) once daily, for a total dose of 3.0 mg per day for 7 days
Multiple doses, two sprays per nostril
(200 µL per nostril) twice daily (12 hours
apart), for a total dose of 6.0 mg per day
for 7 days

2

12

approximately every 12 hours for 7 days (Table 2). Administration of the third dose among Group 2 participants will be
delayed, enabling investigators to obtain a 24-hour PK timepoint for one completed 6.0 mg BID treatment. Participants
in this group will undergo PK sampling (nasal and nasopharyngeal fluids) at baseline (enrollment visit); on day 2 (1 hour,
6 hours, and 10 hours after the second dose); days 3, 5, and 8
(pre-dose, 1 hour, 6 hours, and 10 hours after the final dose);
and days 9 and 10. Blood for evaluation of systemic exposure
will be collected at baseline, on days 2 and 5, and on day 8
after the final dose completion.
Safety assessment for both groups (Phase 1b) will be conducted after 3 days of dosing, upon completion of the final
dose, and within 3–4 weeks of dose completion. An optional
rectal fluids sampling procedure using a sponge will be performed 1 day after the final dose, to assess for any study product in the gastrointestinal tract. The body has the potential
to generate antibodies against administered drugs. Because
of this, anti-drug antibodies/immunogenicity assays will be
performed at baseline, day 7, and 3–4 weeks after the final
dose administration. All sampling procedures will be performed in the clinic.
Study participants/population
The study population will consist of healthy male or female
individuals who will satisfy the following inclusion criteria.
Inclusion criteria
Participants will be aged 18–65 years at screening, have a
negative SARS-CoV-2 test at screening, provide written informed consent, provide adequate information for locator
purposes, be able to return for subsequent study visits, and
agree not to participate in other research studies involving drugs and/or medical devices during the study period.
In addition, female participants should not be pregnant at
the baseline or enrollment, and not breastfeeding during the
study. They will be encouraged to use contraceptive methods while in the study. Participants must be in general good
health in the opinion of the investigator.
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Exclusion criteria
Participants will be excluded if they have ongoing moderate
to severe allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD), chronic rhinitis or sinusitis. Additionally, participants will not be enrolled if they report ongoing common cold or flu-like symptoms at screening. Participants with known moderate, severe, or higher seasonal
allergies; smokers; those with a history of non-therapeutic
injection and recreational drug use in the six months prior
to screening; and those taking medications such as systemic
steroids and intranasal medicines will not be enrolled.
Study product
The Q-GRFT intranasal spray product to be administered to
subjects in the Phase 1a/1b studies contains Q-GRFT (7.5
mg/mL) as the API (10 mg/mL Q-GRFT stock solution in
phosphate-buffered saline, pH 7.4) and water-soluble preservatives (parabens) in a viscosity modifying agent (lambda
carrageenan polymer), along with a stabilizing agent, an
acidifying agent, and solvents (PBS and purified water). The
placebo intranasal spray used in Phase 1a is identical to the
active product formulation minus the API. In Phase 1a, participants will receive two sprays per nostril (100 µL/spray)
for a total dose of 3 mg Q-GRFT in the active arm group.
The placebo group will receive two sprays per nostril (100
µL/nostril). In Phase 1b, Group 1 participants will receive
two sprays per nostril (total dose 3 mg Q-GRFT) once daily
for seven days, while Group 2 will receive two sprays per
nostril twice daily for seven days.
Study procedures
Participant recruitment, screening, and retention:
Participants will be recruited from a variety of sources, using key strategies that will include: clinician-patient referrals, use of existing “study registries” containing the names
and phone numbers of individuals who have given informed
consent to be reached for future studies for which they may
be eligible, participant referrals (participants may refer their
friends or partners who meet eligibility criteria), and passive
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Study period

Timepoint

Enrollment

Randomization

Visit 0

Visit 1

Enrollment
Eligibility screen

×

×

Informed consent
Medical history
COVID-19 testing

×
×
×

×

Randomization

×

Interventions
Study product dosing

×

Follow-up
Visit 2

Visit 3

Assessments
Physical exam and vitals

×

×

×

×

Nose and throat exam
Nasal, nasopharyngeal, oropharyngeal swab

×
×

×
×

×
×

×
×

Complete blood count

×

×

Comprehensive metabolic panel

×

×

Cytokines evaluation

×

×

Completion
Visit 4

Urinalysis
Plasma (SARS-CoV-2 antibodies)

×
×

Plasma (Q-GRFT detection)
Olfactory function

×

Quality of life

×

×

×

×
×

Product acceptability questionnaire
Adverse events

×

×

×

×

×

×

×

×

Figure 3. Schedule of enrolment, interventions, and assessments for the Phase 1a study.

self-referral by interested individuals who see a study poster
or brochure. Both male and female participants will be recruited, and strategies will be undertaken to ensure equitable
opportunity to enroll for members of both biological sexes to
the greatest possible extent. Additionally, members of minority groups that are representative of the diversity of Jefferson County, Louisville, KY, will be sought. Enrollment will
be performed at the University of Louisville, Louisville, KY.
The schedules of enrolment, intervention, and assessments
for these studies are shown in Figure 3 for Phase 1a and Figure 4a–b for Phase 1b.
Volunteers will be prescreened to determine eligibility. Eighteen participants will be enrolled in Phase 1a, while up to 24
will be recruited in the Phase 1b study.
Efforts will be undertaken to ensure that enrolled participants are retained for the duration of follow-up, minimizing
loss-to-follow-up bias. This will be done through exhaustive explanation of the study visit schedule and procedural
requirements during the informed consent process, both inperson and using a pre-recorded information video, and reemphasis at each study visit; thorough explanation of the importance of all dosing and sampling phases to the overall success of the study; use of appropriate and timely visit reminder
mechanisms (via email and/or telephone); and immediate and
Univ Louisville J Respir Infect | Vol. 6, iss. 1: a22

multifaceted follow-up on missed visits.
Informed consent, clinic visits, and assessment: All
participants will provide written informed consent prior to
participation in the study. Participants will have a right to
withdraw from the study at any time for any reason.
Participants will be prescreened using online questionnaires
and telephone interviews, and selected volunteers will be invited for the screening visit at the clinical trials unit.
In the Phase 1a study, at Visit 0, written informed consent will
be obtained, along with locator information, demographics,
and medical history. A brief physical examination, including a visual inspection of the nose and throat and an assessment of olfaction, will be conducted. A baseline quality-oflife questionnaire (Short Form-12 item [SF-12]) will also be
administered. Blood, urine, nasal, and throat specimens will
be collected from eligible participants and a rapid COVID-19
test performed. Baseline specimens (plasma samples; nasal,
nasopharyngeal, and oropharyngeal fluids) will be collected
using a swab for baseline PK, pharmacodynamics (PD), and
cytokines evaluation.
Three to four days after screening (Visit 0), Visit 1 (enrollment and single-dose exposure) will occur. Eligibility will

Nabeta et al. (2022) | 7
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a) Group 1
Study period

Timepoint

Screening

Enrollment

Visit 0

Visit 1

Enrollment
Eligibility screen

×

×

Informed consent
Medical history
COVID-19 testing

×
×
×

Interventions
Study product dosing

Follow-up

Completion

Visit 2

Visit 3

Visit 4

Visit 5

Visit 6

Visit 7

×

×

×

×

×

×

×

×

×

×

×

Assessments
Physical exam and vitals

×

×

×

×

×

×

×

Nose and throat exam
Nasal, nasopharyngeal swab

×
×

×
×

×
×

×
×

×
×

×
×

×
×

Complete blood count

×

×

Comprehensive metabolic panel

×

×

Cytokines evaluation

×

×

Urinalysis

×

×

Plasma (SARS-CoV-2 antibodies)

×

Olfactory function

×

Quality of life

×

×
×

×

×
×

Product acceptability questionnaire
Adverse events
Optional rectal sampling

×

×

×

×

×

×

×

×

×
×
×

×

×

×

×

Figure 4. Schedule of enrolment, interventions, and assessments for the Phase 1b study.

be confirmed and a complete clinical assessment performed.
Plasma samples will be obtained and stored for future research, and repeat blood tests will be performed where indicated for follow-up of any prior abnormal blood tests. Participants will then receive either the single-dose Q-GRFT API
intranasal spray or placebo, two sprays into each nostril, per
the randomization assignment, administered by the study
clinician. PK sample collection will then occur at 1 hour and
6 hours post dosing.
Visit 2 will occur 24 hours post dosing and include clinical
evaluation and PK sampling. Nasal, nasopharyngeal, and
oropharyngeal fluids will be collected. Blood will be collected for cytokine evaluation and plasma stored for future
research. Olfaction will be assessed using the Brief Smell
Identification Test (BSIT), and an acceptability questionnaire
will be completed.
Visit 3 will be the final safety evaluation and PK sampling
visit, occurring two days after visit 2. Participants will complete a product acceptability questionnaire and the SF-12 and
will receive a symptom-directed physical exam, including a
nose and throat inspection. Olfaction will also be assessed.
Blood will be collected for full hemogram and storage. In addition, nasal, nasopharyngeal, and oropharyngeal fluids will
Univ Louisville J Respir Infect | Vol. 6, iss. 1: a22

be collected and the product acceptability questionnaire administered.
A final Phase 1a study exit phone call (Visit 4) will be made
within 2–3 weeks after visit 3 to inquire about any adverse
events that the participant may have experienced as a result
of product administration. The product acceptability questionnaire will be administered again in an online format. If
the safety and tolerability of the single dose exposure is confirmed in Phase 1a, the study will proceed to Phase 1b.
Participants in Phase 1b will be enrolled and stratified into
two groups. In Group 1, up to 12 participants will receive a
dose of 3.0 mg intranasal Q-GRFT once daily, administered
as two sprays (100 µL/spray) in each nostril, for seven days.
The initial dose will be administered in the clinic by a clinician. Participants will be taught how to self-administer the
study product at the clinic and receive written instructions
for at-home self-administration. Subsequent doses will be
self-administered either at the clinic or at home. Sampling
will be performed for PK (nasal and nasopharyngeal fluids)
at baseline (enrollment visit), on day 1 (1, 6, and 10 hours after the initial dose), day 2 (24±1 hours after initial dose), day
4 (pre-dose and 1-hour post-dose), day 7 (pre-dose; 1, 6, and
10 hours after the final dose), day 8 (24±1 hours), and day 9
Nabeta et al. (2022) | 8
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(48±2 hours) following the final dose. Blood for evaluation
of systemic exposure will be collected at baseline, days 1 and
4 (1 hour post-dose), and on day 7 upon dose completion.
Group 2 participants will be enrolled after all participants in
Group 1 have been enrolled and at least six participants have
received all seven doses, with a safety review done.
In Group 2, up to 12 participants will be enrolled to receive
a total of 6.0 mg intranasal Q-GRFT, administered as 3.0 mg
twice daily (3.0 mg BID) as two sprays (100 µL/spray) in each
nostril approximately every 12 hours for seven days. Administration of the third dose will be delayed so that a 24-hour PK
timepoint for one completed 6.0 mg BID treatment dose can
be obtained. The initial dose will be administered in the clinic
by a clinician. Participants will be taught to self-administer
the study product at the clinic and receive written instructions for at-home self-administration. Subsequent doses will
be self-administered either at the clinic or at home. Sampling
will be performed for PK (nasal and nasopharyngeal fluids) at
baseline (enrollment visit), on day 2 (1, 6, and 10 hours after
the second dose), day 3 (24±1 hours after the second dose),
day 5 (pre-dose after 3 completed doses of 6 mg and 1 hour
post-dose), day 8 (pre-dose; 1, 6, and 10 hours after the final
dose), day 9 (24±1 hours) and day 10 (48±2 hours) following
the final dose. Blood for evaluation of systemic exposure will
be collected at baseline, on days 2 and 5 (1 hour post-dose),
and on day 8 after the final dose completion.
Safety assessment for both groups will be conducted after
three days of dosing, upon completion of the final dose, and
within 3–4 weeks of dose completion. An optional rectal fluids sampling procedure using a sponge will be performed one
day after the final dose to assess for any study product in
the gastrointestinal tract. Blood draws for anti-drug antibodies/immunogenicity assays will be performed at baseline, 6
hours after the last dose, and 3–4 weeks after the final dose
administration. All specimen sampling procedures will be
performed at the clinical trials unit, University of Louisville
Hospital (Figures 1 and 2).
Drug and dose selection: Our extensive studies with rectal toxicology in rats and rabbits did not reach a maximum
tolerated dose, even though animals were dosed with a 30
mg/mL gel formulation that delivered a tissue concentration
measured in PK assays at more than 1,000 fold the EC90 of
HIV-1.[39] Both mice and Syrian Golden hamsters have been
treated with GRFT intranasally in efficacy studies against
SARS-CoV [22] and NiV [18], respectively. Rhesus macaques
have been exposed to nebulized GRFT. No toxicity has been
reported in these studies, and this anticipation extends to the
studies described in this proposal. Evidence of Q-GRFT distribution to the brain is perhaps the most significant toxicity
risk that we may encounter, which will result in the need for
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extensive neurotoxicity assessments in the toxicology studies
planned to support Phase 2 clinical studies.
Based on efficacy observed in the SARS-CoV, NiV, and MERSCoV models, 7.5 mg/mL of Q-GRFT (total dose of 3.0 mg)
will be administered to participants in Phase 1a. This dose
is 1,000-fold higher than the effective dose (EC50 ) that was
protective in tissue exposure experiments performed by our
group (unpublished).
Outcome measures
Phase 1a will determine the safety, acceptability, and PK of
a single dose exposure of Q-GRFT administered intranasally.
Phase 1b will evaluate the safety, tolerability, and pharmacokinetics of multiple doses of Q-GRFT administered intranasally. Safety will be assessed by incidence of adverse
events, acceptability by a rating score from participants, and
PK by detection of drug levels in nasal fluids collected.
Safety and tolerability
Clinical laboratory tests: Hematology, blood chemistry,
and urinalysis will be performed for participants, as described in Figures 3 and 4. A complete blood count with
differential, blood chemistry, urinalysis, and pregnancy test
(βhCG) for female volunteers will be performed at the
screening visit, with repeat hematology and a comprehensive metabolic panel performed at Visit 3, for Phase 1a participants. Evaluation for hematology, blood chemistry, and urinalysis will be performed for Phase 1b participants at screening, with repeat tests on days 2, 5, and 8. The screening tests
will establish baseline values, while repeat tests will allow
the assessment of any impact of intranasal Q-GRFT on body
physiologic parameters.
Physical examination and nasal endoscopy: A physical examination will be performed per Figures 3 and 4.
An abbreviated physical examination—including a nose and
throat exam and routine examination of the lungs, heart, abdomen, skin, and central nervous system—will be performed.
Subsequent nasal endoscopy will be performed by the study
rhinologist during PK sample collection to ensure accuracy
and consistency at all time points. The direct visualization
afforded by endoscopy will allow investigators to swab the
same anatomic location at each sampling time point, reducing sampling variability.
Vital signs: Vital signs (heart rate, blood pressure, temperature, and respiratory rate) will be measured as specified
in Figures 3 and 4 after the subject sits quietly for five minutes on all visits and as clinically indicated. This will allow
the determination of any changes that may be attributed to
product use.
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b) Group 2
Study period

Timepoint

Screening

Enrollment

Visit 0

Visit 1

Enrollment
Eligibility screen

×

×

Informed consent
Medical history
COVID-19 testing

×
×
×

Interventions
Study product dosing

Follow-up

Study completion

Visit 2

Visit 3

Visit 4

Visit 5

Visit 6

Visit 7

Visit 8

×

×

×

×

×

×

×

×

×

×

×

×

×

Assessments
Physical exam and vitals

×

×

×

×

×

×

×

×

Nose and throat exam
Nasal, nasopharyngeal swab

×
×

×
×

×
×

×
×

×
×

×
×

×
×

×
×

Complete blood count

×

×

×
×

Comprehensive metabolic panel

×

×

Urinalysis

×

×

Plasma (SARS-CoV-2 antibodies)

×

Olfactory function

×

Quality of life

×

×
×

×
×
×

Product acceptability questionnaire
Adverse events
Optional rectal sampling

×
×

×

×

×

×

×

×

×

×
×

×

×

×

×

Figure 4 (cont’d).

Bodyweight and height: Bodyweight and height will be
recorded at the initial health assessment.
Olfactory assessment: Evaluation of olfactory function
will be performed at the time points specified in Figures 3
and 4. Sense of smell will be determined using the University of Pennsylvania BSIT, a validated assessment of olfactory function.[40] The BSIT assesses an individual’s ability
to detect odors at a suprathreshold level. The test consists of
12 items provided in a 12-page booklet. On each page, there
is a “scratch and sniff” strip embedded with a microencapsulated odorant along with four choice options. The participant
smells the strip and chooses the odor from the four choices
listed.[41] Scores range from 0 to 12. The BSIT has demonstrated good reliability (r=0.71) and takes less than five minutes to complete.
Any clinically significant change from baseline on follow-up
assessments will be recorded as an adverse event (AE). If the
changes are persistent, a full neurological evaluation will be
performed.
Quality of life: Quality of life will be determined by the
SF-12, a truncated, reliable version of the SF-36. The SF-12
uses 12 questions to evaluate eight domains that provide a

Univ Louisville J Respir Infect | Vol. 6, iss. 1: a22

general assessment of health-related quality of life from the
participant’s perspective.[42] The SF-12 includes subscales to
assess mental and physical functioning. Subscales are scored
according to publisher specifications and standardized to allow comparison with the general US adult population.
Any clinically significant change from baseline on follow-up
assessments will be recorded as an adverse event (AE). If the
changes are persistent, a full neurological evaluation will be
performed.
Product acceptability assessment: Product acceptability, feasibility, and tolerability will be evaluated by a questionnaire as specified in Figures 3 and 4. Questionnaire
items are derived from existing, validated questionnaires,
adapted for the current study.[43] Participant experience and
opinion of efficacy, sensory perceptions, spray characteristics, administration process, applicator design, and use regimen will be assessed. Responses help determine product
characteristics disliked or considered likely to challenge future sustained use by participants. Items are rated on 5-point
Likert scales. The proportion of participants reporting product characteristics considered a barrier to use will be calculated. A Likert scale rating of lower than 3/5 on a given item
will be considered a ‘dislike’ or potential barrier to future
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Pharmacokinetics assessment and ex vivo efficacy:
Per Figure 3, in Phase 1a, nasal, nasopharyngeal, and
oropharyngeal swabs will be collected at visits 0 (baseline), 1
(enrollment), 2 (24 hours post dose), and 3 (3 days post dose),
to determine the drug concentration. In Phase 1b, Group 1
(Figure 4a), nasal and nasopharyngeal samples will be collected at visits 0 (baseline), 1 (enrollment), 2 (day 2 of dosing),
3 (day 4 of dosing), 4 (day 7 of dosing), 5 (24 hours after final
dose), and 6 (48 hours post final dose). In Phase 1b Group 2
(Figure 4b), nasal and nasopharyngeal samples will be collected at visits 0 (baseline), 1 (enrollment), 2 (day 2 of dosing),
3 (day 3 of dosing), 4 (day 5 of dosing), 5 (day 8 of dosing),
6 (24 hours post final dose) and 7 (48 hours post final dose).
Inhibition of SARS-CoV-2 infectivity will be assessed ex vivo
by plaque reduction neutralization assay (PRNT), and correlations with Q-GRFT drug levels will be established.
Tolerability assessment and management—adverse
events: Throughout the study, each participant’s condition will be closely monitored. Signs and symptoms of
possible adverse events (AEs) will be reported by the study
participants or observed by staff. They will be elicited from
the participants by using direct or indirect questions, such
as “How have you felt since your last visit to the clinic?”
and “Have you experienced any changes in your wellbeing
since receiving the study product?” All AEs, whether
reported by the subject, elicited by staff, or observed by
the investigator, will be recorded. The start and end dates,
AE-specific severity, relationship to study drug, and any
actions taken to address the AE will also be documented.
Outcomes, such as whether an AE results in death, requires
or necessitates hospitalization, or causes any persistent or
significant disability/incapacity; any intervention to prevent
these outcomes; and whether the events and actions taken
were reported to the Data and Medical Monitor, Institutional
Review Board (IRB), and study sponsor, will be recorded.
Serious adverse events (SAEs) occurring in a study participant or any worsening of SAEs at any time during the study
will be elicited and reported within 24 hours to the investigator, who will then immediately inform the Medical Monitor
and IRB. If any pregnancy occurs during the study, the investigator will immediately notify the Medical Monitor and IRB
upon learning of the occurrence.
Tolerability of Q-GRFT in study volunteers will be derived
from the frequency of AEs and study withdrawal due to any
reported discomfort during the dosing period. Per Figures
3 and 4, blood samples will be collected as previously described. Although not expected, if systemic toxicity is identified following drug administration, the subject will be reevaluated with a full physical examination and repeat blood
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tests to confirm toxicity. If the repeat tests are normal, this
will be documented. Additionally, if still abnormal, appropriate action will be taken and/or subsequent blood draws
performed serially until resolution is documented.
Sample and data storage: Samples and data collected
will be stored at the University of Louisville Clinical Trials
Unit (CTU) and the Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM) laboratory,
Louisville, KY. IRB approval will be sought for all the study
procedures. Consent for sample collection and data storage will be provided by participants. All biospecimens collected will be de-identified, processed, and analyzed blindly
until study completion. Similarly, electronic data will be deidentified, stored on secured servers with encryption, and
accessed only by authorized users. A Research Electronic
Data Capture (REDCap® ) online database system hosted at
the University of Louisville will be utilized to store, secure,
organize, and analyze data.[44] Responses on paper questionnaires will be entered into REDCap® by study personnel. Upon conclusion of the study, the de-identified stored
specimens and data will be made available for use by other
researchers and investigators upon request to the Principal
Investigator.
Planned analyses
Data analyses: All participants who receive the study
product (placebo and active drug in Phase 1a, and active drug
in Phase 1b) will be included in the safety and efficacy analyses. All intra-and inter-participant outcome measures collected during the study period will be analyzed by an experienced biostatistician.
Data will be summarized following recommended standard
guidelines. Data from sets of patients that complete each
study visit and any reasons for early study termination will
be noted and compared across study arms. Descriptive statistics (median, mean, standard error, standard deviation, minimum, and maximum) will be used to summarize data for
doses received and study visits completed. Similarly, demographic and baseline characteristics for participants in
all groups will be summarized using descriptive statistics.
Drug concentrations over the study period will be compared in both nasal cavities/epithelia and plasma to determine changes over time. Biomarker changes between preand post-dosing will be analyzed using paired tests. Descriptive summary statistics will be reported according to observed data, and missing data will not be imputed. Bayesian
and likelihood estimates will be used for limited analyses
where formal inferential statistics will be required for participants with missing follow-up assessments. A P-value ≤0.05
will be considered statistically significant.
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Table 3. Analysis of safety event frequency for arms of size 12 (Q-GRFT nasal spray).

Event rate (%)

P (0 events)

P (≥1 events)

P (≥2 events)

P (≥3 events)

1
5
10
15
25
35
45

0.886
0.540
0.282
0.142
0.032
0.006
0.001

0.114
0.460
0.718
0.858
0.968
0.994
0.999

0.006
0.118
0.341
0.557
0.842
0.958
0.992

0.000
0.020
0.111
0.264
0.609
0.849
0.958

Table 4. Analysis of safety event frequency for arms of size 6 (placebo spray).

Event rate (%)

P (0 events)

P (≥1 events)

P (≥2 events)

P (≥3 events)

1
5
10
15
25
35
45

0.941
0.735
0.531
0.377
0.178
0.075
0.028

0.059
0.265
0.469
0.623
0.822
0.925
0.972

0.001
0.033
0.114
0.224
0.466
0.681
0.836

0.000
0.002
0.016
0.047
0.169
0.353
0.558

Safety analyses:
Concomitant/ongoing medications: Any concomitant medications, including those not related to the study product, will
be coded according to the World Health Organization (WHO)
drug dictionary and tabulated by dosing group.
Adverse events: Incidence of all treatment-related AEs and
treatment-emergent AEs (TEAEs) will be summarized. A
TEAE is an event that first occurs or worsens in intensity
following the administration of a study drug. The Medical
Dictionary for Regulatory Activities (MedDRA) will be used
to classify AEs by system organ class and preferred term. For
incidence reporting, when participants report more than one
AE coded to the same system organ class or preferred term,
the participant will be counted only once for that system organ class or preferred term. Events that occur between the
signing of informed consent and the first study drug administration will be recorded. A list of possible AEs, including the
participant incidence of TEAEs, treatment-related AEs, SAEs,
deaths, and AEs resulting in study termination, will be constructed. For the stratification of AEs by severity, the worst
severity for each participant during the study will be presented. Appropriate generalized linear models will be used
for comparisons of significant differences between groups.
In addition, for the safety analysis, the number and frequency
of ≥Grade 2 AEs and ≥Grade 1 nasal cavity-related AEs will
be tabulated for the intranasal administration method. To determine whether AEs are occurring excessively, the propor-
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tion of subjects that experience an AE will be calculated for
each method of administration. A single summary outcome
of this type (yes/no) can be reasonably assumed to follow
a Bernoulli distribution. Tables 3 and 4 show, for selected
true underlying rates between 0.01 and 0.45, the probability
of zero, one or more, and two or more subjects experiencing
AEs in a sample group of participants, for the Phase 1a study.
With regard to safety, the Phase 1a study will be paused for
clinical data safety review in the event that four or more
study participants in the treatment arm or two or more participants in the placebo arm experience an AE ≥Grade 3.
With 18 total subjects, the probability of three or more AE
≥Grade 3 events occurring given a true ≥Grade 3 AE rate is
shown in Table 5.
In Phase 1b, the study will pause for clinical data safety review in the event that three or more study participants experience an AE ≥Grade 3. With up to 24 total participants,
the probability of three or more AE ≥Grade 3 events occurring given a true ≥Grade 3 AE rate is shown in Table 6.
Table 7 shows the analysis of safety event frequency with
a group size of 12 for participants who receive the Q-GRFT
nasal spray.
Serious adverse events: In a similar manner to AEs above,
SAEs will be listed and summarized. The sponsor will be notified of any SAEs within 24 hours of their discovery.
Clinical laboratory results: Blood samples will be evaluated
in a qualified clinical laboratory. Descriptive statistics will be
Nabeta et al. (2022) | 12
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Table 5. Analysis of safety event frequency for both arms of size 18.

Event rate (%)

P (0 events)

P (≥1 events)

P (≥2 events)

P (≥3 events)

1
5
10
15
25
35
45

0.835
0.397
0.150
0.054
0.006
0.000
0.000

0.165
0.603
0.850
0.946
0.994
1.000
1.000

0.014
0.226
0.550
0.776
0.961
0.995
1.000

0.001
0.058
0.266
0.520
0.865
0.976
0.997

Table 6. Analysis of safety event frequency for both groups of size 24.

Event rate (%)

P (0 events)

P (≥1 events)

P (≥2 events)

P (≥3 events)

1
5
10
15
25
35
45

0.786
0.292
0.080
0.020
0.001
0.000
0.000

0.214
0.708
0.920
0.980
0.999
1.000
1.000

0.024
0.339
0.708
0.894
0.991
1.000
1.000

0.002
0.116
0.436
0.720
0.960
0.997
1.000

used for actual values, and any changes from baseline will be
tabulated by study visit. Clinical laboratory values outside of
normal reference ranges post baseline will be recorded and
analyzed using appropriate binary measures. Any changes
from baseline to worsening severity in laboratory values will
be recorded and analyzed with appropriate test statistics.
Vital signs: Data observed at baseline and any change from
baseline will be determined for all measurements at clinic visits. These data will be summarized with descriptive statistics
and analyzed using an appropriate generalized linear mixed
model.
Statistical analysis for study objectives: As mentioned
above, patients will be closely monitored for any AEs or toxicity with repeat blood draws until AE resolution. To account
for inherent correlation, repeated measures statistics will be
included in a repeated measures factor analysis with random
effects. For the exploratory objectives, correlations will be
determined between Q-GRFT drug levels obtained at PK sampling and SARS-CoV-2 infectivity in vitro and ex vivo. For
olfactory sensation and quality of life, Spearman’s statistics
and Student’s t-tests will be used for correlation analysis and
comparisons between groups, respectively.

Discussion
The initial SARS-CoV pandemic was reported in 2002–2003
[13] while MERS-CoV outbreaks have continued to date since
the first human case was identified in 2012.[14, 15] CoronUniv Louisville J Respir Infect | Vol. 6, iss. 1: a22

aviruses have also been responsible for seasonal noncomplicated upper and lower respiratory tract infections.[45, 46]
The ongoing COVID-19 pandemic caused by SARS-CoV-2
has resulted in unprecedented disruption in peoples’ lives
and had a serious negative impact on healthcare operations and the economy. Unlike the responses to the multiple epidemics and pandemics caused by coronaviruses in
the past, the current COVID-19 pandemic has resulted in
rapid and fast-paced development of effective vaccines to
curb infection.[47]
Treatments that have received either Emergency Use Authorization or full approval by the U.S. Food & Drug Administration (FDA) for utility in treatment and/or prevention include Remdesivir [48]; monoclonal antibodies, such as sotrovimab and casirivimab plus imdevimab; and vaccines, including products marketed by Pfizer-BioNTech, Moderna, and
Johnson & Johnson.[49] The search for more effective approaches and treatments is on-going.[50, 51] To supplement
these strategies, a non-vaccine broad-spectrum prophylactic
nasal spray is an ideal adjunctive approach to prevent virus
infection and transmission. This is warranted since the longterm durability of antibodies in the elderly and immunocompromised individuals following vaccination is still under
investigation.[52] Furthermore, vaccinated and previously
infected individuals are still susceptible to re-infection with
SARS-CoV-2.[29, 53] In addition, viral loads in asymptomatic
individuals are high, with the virus easily transmissible.[54]
The current spread and transmission of new viral variants
complicate the current authorized/approved therapeutic and
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Table 7. Analysis of safety event frequency for group size of 12 (Q-GRFT nasal spray).

Event rate (%)

P (0 events)

P (≥1 events)

P (≥2 events)

P (≥3 events)

1
5
10
15
25
35
45

0.886
0.540
0.282
0.142
0.032
0.006
0.001

0.114
0.460
0.718
0.858
0.968
0.994
0.999

0.006
0.118
0.341
0.557
0.842
0.958
0.992

0.000
0.020
0.111
0.264
0.609
0.849
0.958

prevention modalities.[55]
Studies have shown that intranasal sprays can decrease the
risk of acquisition and establishment of viral respiratory infections. In rodent models, an intranasal spray with low pH
gel and antibody prophylaxis prevented infection with influenza virus.[56, 57] Pilot studies in humans with hypertonic
nasal saline irrigation [58] and rupintrivir nasal spray [59]
have demonstrated efficacy against viral upper respiratory
infections, including rhinovirus colds. Our group and other
researchers have shown that GRFT inhibits viral entry of all
coronaviruses tested, including SARS-CoV, MERS-CoV, and
SARS-CoV-2.[16, 21, 22] Moreover, delivery of GRFT to the
upper respiratory tract provides significant protection from
SARS-CoV [60], MERS-CoV (unpublished), and paramyxovirus Nipah virus [18] in animal models.
Given the existential need for prophylactic interventions
to prevent the spread of the SARS-CoV-2 and other coronaviruses, Q-GRFT API in an intranasal spray will likely provide an additional opportunity to protect against SARS-CoV2 infection and transmission.
Our PREVENT-CoV Phase 1a/1b study will assess the safety,
acceptability, and pharmacokinetics of Q-GRFT intranasal
spray as broad-spectrum prophylactic for coronavirus infections. This study will be the first proof of concept trial to determine whether a Q-GRFT intranasal spray formulation is
safe and acceptable for human use. Clinically relevant endpoints have been carefully selected, including olfactory function and determination of PK parameters. Q-GRFT intranasal
spray is a topically administered product with a low likelihood of systemic side effects.[39, 61] Although the expectation is the demonstration of a low risk of toxicity, careful assessments of safety, including systemic symptomatology, will
be undertaken in this trial with special consideration for issues related to central nervous system toxicity. This is due to
the potential for Q-GRFT exposure via the olfactory epithelium when administered through the nasal route. The design
of this study will allow for the exploration of these questions
while protecting the safety of participants.
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For the drug to prevent coronavirus infection, it is critical
that the product must be present in the appropriate anatomical site and at the ideal concentration throughout the period of exposure to infection. Consequently, the multicompartmental PK included in this study will generate important
data that, in combination with the SARS-CoV-2 neutralization findings, will help determine whether the test product
has the appropriate profile to support further development
in future clinical trials.
Trial status
Approval to conduct this study was granted by the University
of Louisville Institutional Review Board (IRB), (Phase 1a IRB#
21.0704 and Phase 1b IRB# 22.0224). FDA approval for use
of intranasal Q-GRFT has been granted under IND 151381.
The ClinicalTrials.gov identifier for the Phase 1a study is
NCT05122260 and for Phase 1b is NCT05437029. Participant
recruitment for the Phase 1a trial commenced on November
11, 2021 and was completed on February 14, 2022. Recruitment for the Phase 1b study started on June 15, 2022, and the
last study visit occurred on September 8, 2022. The anticipated study completion date is November 1, 2022.
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